Neogen (NEOG)
(Delayed Data from NSDQ)
$14.44 USD
+0.16 (1.12%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $14.45 +0.01 (0.07%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.44 USD
+0.16 (1.12%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $14.45 +0.01 (0.07%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
Neogen's (NEOG) Soleris for EBAC Receives AOAC's Clearance
by Zacks Equity Research
Neogen's (NEOG) Soleris test gets clearance from the AOAC, paving the way for efficient prevention of food contamination.
Neogen's Food Safety Business Thrives on Ergot Alkaloids Test
by Zacks Equity Research
The newly-developed Reveal Q+ MAX test is likely to fortify Neogen's (NEOG) presence in the global food allergen testing market.
Neogen (NEOG) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EYE or NEOG: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EYE vs. NEOG: Which Stock Is the Better Value Option?
Neogen's (NEOG) Food Safety Test Receives AOAC Clearance
by Zacks Equity Research
Neogen's (NEOG) Reveal 3-D safety test for checking peanut contamination in food items gets approval from the AOAC.
Why Is Neogen (NEOG) Down 2% Since Last Earnings Report?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Neogen (NEOG) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -3.45% and -3.47%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Neogen Forms Partnership With IGS to Enhance Beef Profile
by Zacks Equity Research
Neogen (NEOG), through the IGS partnership, aims to help cattle producers choose better cattle and enhance their productivity.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety
by Zacks Equity Research
Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.
Why Is Neogen (NEOG) Up 4.4% Since Last Earnings Report?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Neogen's (NEOG) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Neogen's (NEOG) strong international business and solid performance by core Food Safety segment resulted in year-over-year revenue growth.
Neogen (NEOG) Tops Q4 Earnings Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 7.14% and -1.09%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Neogen (NEOG) Q4 Earnings Expected to Decline
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold Onto Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors' trust continues to be high in Neogen (NEO), thanks to strength in its Food Safety and Genomic businesses.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Why Is Neogen (NEOG) Up 4.2% Since Last Earnings Report?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen Hurt by Weakness in Animal Safety, Currency Woes
by Zacks Equity Research
Neogen (NEOG) exits fiscal third quarter on a disappointing note due to poor performance of Animal Safety segment.
Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.
Earnings Preview: Neogen (NEOG) Q3 Earnings Expected to Decline
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH